Sign In
Buy AMGN
$338.22
+9.96 (+3.03%)
At Close: Jun 03, 2026
Amgen collaborates with Arrakis targeting multiple therapeutic areas
02:24pm, Tuesday, 11'th Jan 2022 Seeking Alpha
Amgen (AMGN) and Arrakis Therapeutics announce a research collaboration focused on the discovery and development of RNA degrader therapeutics against a range of difficult-to-drug targets
Why the Earnings Surprise Streak Could Continue for Amgen (AMGN)
01:50pm, Tuesday, 11'th Jan 2022
Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Amgen, Inc. (AMGN) CEO Robert Bradway Presents at 40th Annual J.P. Morgan Healthcare Conference (Transcript)
01:44pm, Tuesday, 11'th Jan 2022
Amgen, Inc. (AMGN) CEO Robert Bradway Presents at 40th Annual J.P. Morgan Healthcare Conference (Transcript)
Amgen (AMGN) Gains As Market Dips: What You Should Know
07:54pm, Monday, 10'th Jan 2022
Amgen (AMGN) closed at $230.37 in the latest trading session, marking a +1.36% move from the prior day.
Amgen: Still A Good Pick For Bargain Hunters
02:11pm, Monday, 10'th Jan 2022
Amgen reported solid results in the last quarter and the long-term growth story is still intact.
Europe Approves Amgen''s KRAS-Targeted Lung Cancer Therapy
12:24pm, Monday, 10'th Jan 2022 Benzinga
The European Commission (EC) has granted conditional marketing authorization to Amgen Inc''s (NASDAQ: AMGN ) Lumykras (sotorasib), a KRASG12C inhibitor, for non-small cell lung cancer (NSCLC). The approval covers adult NSCLC patients with KRAS G12C mutation and who have progressed after at least one prior line … Full story available on Benzinga.com
EC approves Amgen''s Lumykras for patients with KRAS G12C-mutated lung cancer
07:19am, Monday, 10'th Jan 2022 Seeking AlphaMy 3 Top Biotech Stock Picks for 2022
02:00pm, Sunday, 09'th Jan 2022
These stocks are poised for a strong year.
Amgen Is Still A Fit For Your Dividend Growth Portfolio
12:06am, Sunday, 09'th Jan 2022
Amgen remained flat during 2021, yet the fundamentals keep improving. The company pays a growing dividend for almost 10 years.
Amgen: You Won''t Regret Buying This Blue-Chip Biotech Stock
05:01pm, Friday, 07'th Jan 2022 Seeking AlphaAmgen (AMGN) Inks Multi-Target Deal to Make Protein Therapeutics | Investing.com
04:40pm, Friday, 07'th Jan 2022 Investing.com
Stocks Analysis by Zacks Investment Research covering: Amgen Inc, NVIDIA Corporation, Boston Beer Company Inc, Five Prime Therapeutics Inc. Read Zacks Investment Research''s latest article on Investing.com
Amgen: You Won't Regret Buying This Blue-Chip Biotech Stock
12:01pm, Friday, 07'th Jan 2022
Amgen's midpoint non-GAAP diluted EPS payout ratio will be 41.9% for this year and will only slightly expand to 43.2% next year, despite the recent 10.2% dividend hike. Even with continued COVID-19 he
Amgen (AMGN) Inks Multi-Target Deal to Make Protein Therapeutics
11:33am, Friday, 07'th Jan 2022
Amgen (AMGN) signs a collaboration agreement with Generate Biomedicines to develop protein therapeutics across several therapeutic areas and multiple modalities.
Amgen, Inc. (AMGN) Presents at Goldman Sachs 14th Annual Healthcare CEOs Unscripted Broker Conference Call - (Transcript)
09:07pm, Thursday, 06'th Jan 2022 Seeking AlphaAmgen, Inc. (AMGN) Presents at Goldman Sachs 14th Annual Healthcare CEOs Unscripted Broker Conference Call - (Transcript)
04:07pm, Thursday, 06'th Jan 2022
Amgen, Inc. (AMGN) Presents at Goldman Sachs 14th Annual Healthcare CEOs Unscripted Broker Conference Call - (Transcript)
